Geode Capital Boosts Zomedica Bet

Veterinary Medicine Stocks News

According to a recent Form 13F filing submitted to the SEC, Geode Capital Management disclosed a noteworthy and bullish investment in ZOM stock. Here’s what you need to know about Zomedica Corp., as well as Geode Capital Management and their long position in shares of ZOM stock:

About Geode Capital Management

Boston, Massachusetts-based Geode Capital Management, LLC is a systematic asset manager providing core beta exposures across a range of equity and niche asset classes. Geode was founded in 2001 and set out to create structured and repeatable investment strategies with the objective of providing efficient exposures to institutional investors.

About Zomedica Corp. (ZOM)

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Geode Capital Management Buys Stock in ZOM

According to the most recent 13F filed by Geode Capital Management, the firm added 10,417 shares of ZOM stock to it holdings in the recent quarter. That brings their total long position in Zomedica Corp. to 8,938,129 shares, representing approximately 0.9121% of the 979,950,040 ZOM shares outstanding. Based on the most recent closing price of $0.24 per share of ZOM, the entire Geode Capital Management position in Zomedica Corp. is worth roughly $2,144,257.15.


Be sure to check out more recent 13F filings here to stay up to date on the latest disclosures from institutional investment managers like Geode Capital Management. Also be sure to check out more recent 13F filing analysis news here.

Related Articles